The Effect of Ultrasound-Guided Multipoint Thoracic Paravertebral Nerve Block in Metabolic and Bariatric Surgery (MBS): A Prospective Randomized Controlled Trial - Top-Institutions - MDSpire

The Effect of Ultrasound-Guided Multipoint Thoracic Paravertebral Nerve Block in Metabolic and Bariatric Surgery (MBS): A Prospective Randomized Controlled Trial

  • By

  • Lijuan Li

  • Jing Wang

  • Tao Hu

  • Junmei Xu

  • Jiapeng Huang

  • August 18, 2025

  • 0 min

Share

Top Institutions in Surgery

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Bariatric Surgery
    • Anesthesiology
    • Pain Medicine

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Bariatric Surgery
    • Anesthesiology
    • Pain Management

  • #3

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Bariatric Surgery
    • Anesthesiology
    • Regional Anesthesia

  • #4

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Bariatric Surgery
    • Anesthesiology
    • Pain Medicine

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Bariatric Surgery
    • Anesthesiology
    • Regional Anesthesia

Original Source(s)

The Effect of Ultrasound-Guided Multipoint Thoracic Paravertebral Nerve Block in Metabolic and Bariatric Surgery (MBS): A Prospective Randomized Controlled Trial

  • by Lijuan Li, Jing Wang, Tao Hu, Junmei Xu, Jiapeng Huang

  • August 18, 2025

Related Content

Medical Oddities: Ancient Practice Calms Modern BP

Ancient workouts, anxious ears, tea gains, limb regrowth, and furry tongues collide.

Correction to: One Anastomosis Gastric Bypass Versus Single Anastomosis Sleeve Jejunal Bypass: Does Duodenal Exclusion Matter?

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.